Neumora Therapeutics Bolsa (NASDAQ: NMRA)

Últimas noticias sobre Neumora Therapeutics (NASDAQ:NMRA) Bolsa

Neumora Therapeutics

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics Inc

Safe &amp; Smart Florida, the group behind Florida&#8217;s failed attempt to legalize recreational cannabis in November 2024, has <a href="https://smartandsafeflorida.com/">launched a new initiative</a> to do it again in a 2026 ballot.
The "Adult Personal Use of Marijuana," initiative was filed on Tuesday, first <a href="https://floridapolitics.com/archives/715832-recreational-pot-supporters-launch-fresh-campaign-to-put-new-measure-on-the-ballot/">reported</a> by Florida Politics, noting that it was the first ballot petition filed in 2025.
The new initiative "Allows adults 21 and older to possess, purchase, or use marijuana for non-medical consumption. Establishes possession limits. Prohibits marketing and packaging attractive to children. Prohibits smoking and vaping in public. Maintains prohibition on driving under influence,&#8221; and more. 
Florida Politics pointed out that the campaign launched this new effort to put legal marijuana up for a vote just one day after Gov. <a href="https://www.benzinga.com/topic/ron-desantis" target="_blank" rel="noreferrer noopener">Ron DeSantis</a> called a special session asking lawmakers to crackdown on &#8220;fraudulent signatures&#8221; to place amendments on the ballot. Leaders of the legislature, per the outlet, said they do not intend to allow DeSantis &#8220;to dictate what issues are ultimately considered by lawmakers.&#8221;
This past November, the ballot measure, known as Amendment 3, <a href="https://www.benzinga.com/markets/cannabis/24/11/41763514/florida-rejects-cannabis-legalization-amendment-supported-by-trump-detested-by-desantis">fell short </a>of the 60% vote required to pass an amendment in Florida though it received nearly 57% support across the state. The amendment faced tough and sustained opposition from DeSantis&nbsp;and the Florida Republican Party.
Over the course of its efforts, Smart &amp; Safe&#8217;s legalization campaign pulled in at least $150 million, making it the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/06/39565658/desantis-anti-cannabis-florida-freedom-fund-raises-barely-a-fraction-of-legalization-committees-" target="_blank" rel="noreferrer noopener">best-funded cannabis legalization</a>&nbsp;initiative in U.S. history, with medical marijuana giant&nbsp;Trulieve Cannabis Corp. (OTC:&nbsp;TCNNF) contributing the bulk of it.
<h1 class="wp-block-heading">Cannabis Stocks Respond</h1>
Cannabis stocks, which had dropped slightly on news that the DEA hearings on rescheduling cannabis <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">were put on hold</a> for three months, seemed to perk up a bit with the Florida initiative news.
ETFs such as AdvisorShares Pure US Cannabis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) rose 0.29% and AdvisorShares Pure Cannabis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>) went up 0.87% at the close. Trulieve Cannabis ended down 2.23% while Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) rose 0.28%. Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) held steady. Other multi-state operators seemed unfazed by the news, at least for now.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">DEA Judge Cancels Marijuana Rescheduling Hearing Amid &#8216;Disturbing&#8217; Allegations Of Improper Conduct</a></li>
</ul>
Photo: El Planteo

Cannabis

Government

News

Regulations

Politics

Legal

Markets

ETFs

GTBIF

MSOS

TCNNF

TLRY

YOLO

Cannabis Legalization Headed For The Ballot Again In Florida: Advocates Launch New Amendment Initiative

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 15 years by 8.74% on an annualized basis producing an average annual return of 20.51%. Currently, UnitedHealth Group has a market capitalization of $500.10 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 15 years ago, it would be worth $15,728.51 today based on a price of $543.42 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736984708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 15 Years

President-elect Donald Trump is considering issuing an executive order aimed at rescuing TikTok from being banned from U.S. app<a href="https://www.benzinga.com/25/01/42931704/tiktok-users-call-on-trump-to-deliver-immediately-on-his-promise-to-save-app-from-us-ban-we-dont-need-the-supreme-court-to"> stores in four days.&nbsp;</a>
What To Know: According to the Washington Post, sources familiar with the matter said Trump is brainstorming strategies to save TikTok from the law signed by President Joe Biden set to ban the app on Sunday. 
Read Next: <a href="https://www.benzinga.com/news/legal/25/01/42979220/biden-announces-more-student-loan-forgiveness-bringing-debt-relief-to-nearly-5-million-borrowers">Biden Announces More Student Loan Forgiveness, Bringing Debt Relief To Nearly 5 Million Borrowers</a>
One of the strategies Trump is considering is an executive order that would suspend enforcement of the law for 60 to 90 days. One source said the president-elect would like to be seen "making a deal" to save the popular social media app. 
It is not clear whether an executive order would keep TikTok in U.S. app stores, overriding a law passed by Congress.&nbsp;
"TikTok will still be banned, and it will still be illegal for Apple and Google to do business with them. But it will make the president's intention not to enforce the law that much more official," Alan Rozenshtein, a former national security adviser to the Justice Department, told the Washington Post.&nbsp;
What Else: A Bloomberg report on Monday suggested that Elon Musk is in talks with Chinese officials regarding a potential scenario where Musk's X platform <a href="https://www.benzinga.com/general/social-media/25/01/42965533/elon-musk-emerges-as-potential-tiktok-us-buyer-as-ban-deadline-looms-company-terms-it-pure-fiction">could take over </a>TikTok's U.S. operations.&nbsp;
However, a TikTok spokesperson denied the report telling Benzinga, "We can't be expected to comment on pure fiction."
Other interested parties include Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), as well as a consortium led by the "Shark Tank" investor Kevin O'Leary.
If no deal is reached by the deadline, TikTok <a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone">will be banned</a> from app stores in the U.S. on Sunday, Jan. 19. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42919029/supreme-court-hears-tiktok-oral-arguments">Supreme Court Hears TikTok Arguments With App&#8217;s Ban Ahead: &#8216;Essentially, The Platform Shuts Down&#8217;&nbsp;</a></li>
</ul>
Photo: Shutterstock

Social Media

Tech

General

MSFT

ORCL

Trump Considers Executive Order To 'Save' TikTok From Being Banned In 4 Days

Silicon Valley billionaires are poised to join forces with protectionist hard-liners in Trump&#8217;s second term, marking an alliance that could fundamentally reshape American economic policy.
The incoming administration&#8217;s economic team is a mix of competing interests, including tech industry power brokers and America-first ideologues, creating what The Economist describes as the largest and most diverse group of economic advisers in presidential history.&nbsp;
At its center is Elon Musk, whose new role leading a government efficiency drive signals Trump&#8217;s embrace of tech industry disruption within the federal bureaucracy.
Don't Miss:
<ul>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
Commerce Secretary nominee Howard Lutnick underscores the administration's protectionist tilt, saying before the election, &#8220;You&#8217;ve got to tariff the rest of the world. Keep them the heck out. Bring the manufacturing back here.&#8221; Even traditionally moderate nominees like Treasury pick Scott Bessent and National Economic Council leader Kevin Hassett have endorsed aggressive tariff policies.
The <a href="https://www.benzinga.com/news/24/11/41965420/elon-musk-vivek-ramaswamy-led-department-of-government-efficiency-opens-account-on-x-says-it-is-working-overtime">newly created Department of Government Efficiency (DOGE)</a>, coled by Musk and former presidential candidate Vivek Ramaswamy, could be a direct channel between Silicon Valley and the White House. North Carolina Rep. Dan Bishop told The Economist that the DOGE development marks a &#8220;fundamental change in the dynamic&#8221; of government operations.
Silicon Valley&#8217;s influence extends throughout the administration. Venture capital giant <a href="https://www.benzinga.com/24/11/42253427/elon-musks-doge-dream-team-from-marc-andreessen-to-ubers-travis-kalanick-silicon-valley-titans-join-forces-to-overhaul-federal-spending">Marc Andreessen has spent time at Mar-a-Lago</a> shaping tech policy and personnel decisions. His firm Andreessen Horowitz has placed several partners in key positions, including Scott Kupor as director of the Office of Personnel Management.
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Stephen Miller, appointed deputy chief of staff, will spearhead the America First agenda from within the White House. Miller&#8217;s influence extends beyond immigration policy to broader economic strategy, including a planned two-phase approach beginning with immigration reform and later tackling tax legislation.
Budget director nominee Russ Vought, whom Miller praised as &#8220;the guy for the last four years that has been developing the plan to take down the deep state,&#8221; arrives with a blueprint for restructuring federal agencies. Trade policy remains a central battleground. While Peter Navarro returns as a presidential adviser advocating extensive tariffs, incoming trade representative Jamieson Greer has called for revoking China&#8217;s normal trading status. The administration&#8217;s push for economic decoupling from China creates tension with business interests, including Musk&#8217;s Tesla operations in the country.
Trending: With 100+ historic trademarks including some of the high grossing characters in history, like Cinderella, Snow White and Peter Pan, <a href="https://www.benzinga.com/money/elf-labs-1">this company is transforming the $2 trillion entertainment market with patented AR, VR, and AI tech. — For a short window, investors are able to claim $2/share ($980 min).</a>
Internal conflicts loom between the administration&#8217;s competing factions. Tech leaders advocate for expanded skilled immigration through H-1B visas, while Miller&#8217;s wing pushes for broad restrictions. Even on core Republican principles like tax cuts, divisions have emerged, with former strategist Steve Bannon calling for increased corporate taxation.
The appointment of Miller&#8217;s wife Katie to the efficiency department suggests the America First camp seeks to maintain oversight of the tech contingent&#8217;s reform agenda. Early political challenges, including recent congressional budget negotiations, have already tested the limits of this coalition&#8217;s influence.
As the administration prepares to take office, the alliance of Silicon Valley disrupters, economic nationalists and traditional conservatives must translate campaign promises into coherent policy.&nbsp;
Their success or failure could determine the future of American economic policy for years to come.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Startups

Elon Musk's Role In Shaping Trumponomics: 'You've Got To Tariff The Rest Of The World'

Media company Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) could be in for a tough fourth quarter with concerns about the company's DC Studios reboot, the loss of NBA rights and the underperformance of "Joker: Folie a Deux" <a href="https://www.benzinga.com/general/entertainment/24/10/41210999/joker-2-stumbles-at-box-office-no-laughing-matter-for-warner-bros-stock">at the box office.</a>
These are among the main reasons an analyst is lowering estimates and the price target on Warner Bros. Discovery ahead of fourth-quarter financial results.
The WBD Analyst: Goldman Sachs analyst Michael Ng maintained a Neutral rating on Warner Bros. Discovery and lowered the price target from $10.75 to $9.75.
Read Also: <a href="https://www.benzinga.com/24/12/42603589/disney-hits-2-billion-domestic-box-office-wins-top-honors-global-box-office-2025-to-grow-8-to-33b-analyst-says">Disney Hits $2 Billion Domestic Box Office, Earns Top Honors</a>
The Analyst Takeaways: The analyst expects Warner Bros. to report strong direct-to-consumer additions in the fourth quarter.
Outside of that segment, Ng sees struggles for the media company in other segments including linear networks, advertising and studio. &nbsp;
"WBD stock has outperformed the market since its last earnings report on 11/7/24 during which WBD reached a new agreement with NBA, had an earlier than-expected carriage renewal with Comcast, and announced a new corporate structure plan that splits linear networks business from streaming and studios," Ng said.
The analyst said investor debates will center on topics such as the linear networks outlook, direct-to-consumer momentum and the DC Studios reboot moving forward.
For the DC Studios segment, the analyst lowers the EBITDA target from $874 million to $800 million, citing the underperformance of "Joker: Folie a Duex" at the box office.
While there are concerns about the impact from the flop of "Joker: Folie a Deux" and the <a href="https://www.benzinga.com/general/sports/24/11/42075473/warner-bros-discovery-nba-deal-best-case-scenario-analyst-says-renewal-structure-could-boost-annual-profit">loss of NBA rights,</a> the analyst sees strength ahead for the DTC segment.
"Looking ahead, we estimate WBD can achieve $1.56 bn in DTC EBITDA in 2025E driven by international market launches and content timing."
The analyst highlights international expansion opportunities for the Max streaming platform, password-sharing initiatives, new content, price increases, bundling and ad-lite penetration as catalysts to help power streaming growth.
"Although we're encouraged by WBD's DTC momentum as well as investments in Linear Networks sports programming, the loss of domestic NBA media rights creates mid-term uncertainty in the outlook for Linear Networks profitability," Ng said.
WBD Price Action: Warner Bros. Discovery stock closed Wednesday up .62% to $9.79 versus a 52-week trading range of $6.64 to $12.70. Warner Bros. stock is down 5% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a></li>
</ul>
Photo: Courtesy Warner Bros. Discovery

Analyst Color

Entertainment

Price Target

Reiteration

Analyst Ratings

Media

Warner Bros. Discovery Analyst Says DTC Strength Won't Offset 'Joker: Folie A Deux' Flop, NBA Rights Concerns

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 10 years by 6.11% on an annualized basis producing an average annual return of 17.47%. Currently, Moodys has a market capitalization of $85.42 billion. 
Buying $100 In MCO: If an investor had bought $100 of MCO stock 10 years ago, it would be worth $500.48 today based on a price of $471.35 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736982908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

The U.S. Department of Transportation and Department of Justice jointly filed a lawsuit on Wednesday against Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) for operating "chronically delayed flights" that caused <a href="https://www.benzinga.com/general/travel/25/01/42791291/jetblue-fined-2-million-for-chronic-flight-delays-delta-united-rank-among-most-on-time-airlines">disruptions to passengers. </a>
The Details: DOT said its investigation found Southwest operated two chronically delayed flights, resulting in 180 flight disruptions for passengers between April and August 2022. DOT rules define a chronically delayed flight as one that is flown at least 10 times a month and arrives more than 30 minutes late more than 50% of the time. 
Read Next: <a href="https://www.benzinga.com/news/legal/25/01/42979220/biden-announces-more-student-loan-forgiveness-bringing-debt-relief-to-nearly-5-million-borrowers">Biden Announces More Student Loan Forgiveness, Bringing Debt Relief To Nearly 5 Million Borrowers</a>
"As part of our commitment to supporting passenger rights and fairness in the market for airline travel, we are suing Southwest Airlines for disrupting passengers' travel with unlawful chronic flight delays," Transportation Secretary Pete Buttigieg said in a statement.&nbsp;
"Airlines have a legal obligation to ensure that their flight schedules provide travelers with realistic departure and arrival times. Today&#8217;s action sends a message to all airlines that the Department is prepared to go to court in order to enforce passenger protections," Buttigieg added.&nbsp;
Southwest responded with a statement that it was "disappointed that DOT chose to file a lawsuit over two flights that occurred more than two years ago."
"Any claim that these two flights represent an unrealistic schedule is simply not credible when compared with our performance over the past 15 years," Southwest said.
The lawsuit against Southwest comes only 12 days after the DOT fined JetBlue Airways Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) $2 million for chronic flight delays, which marked the <a href="https://www.transportation.gov/briefing-room/dot-penalizes-jetblue-chronic-flight-delays">first time</a> an airline had been fined for chronic flight delays. 
LUV Price Action: According to Benzinga Pro, Southwest Airlines shares are trading flat after-hours on Wednesday at $32.83.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/42992007/trump-cabinet-confirmation-hearings-on-wednesday-departments-of-transportation-energy-state-attorney-general-cia-director">Trump Cabinet Confirmation Hearings On Wednesday: Departments Of Transportation, Energy, State; Attorney General, CIA Director</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Travel

After-Hours Center

JBLU

Southwest Airlines Is Sued By Department Of Transportation Over 'Chronically Delayed' Flights

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 9.7% on an annualized basis producing an average annual return of 21.06%. Currently, Boston Scientific has a market capitalization of $142.86 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $6,761.34 today based on a price of $97.01 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736982008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Oil prices surged on Wednesday, with West Texas Intermediate light crude rising about 4% to above $80 per barrel for the first time <a href="https://www.benzinga.com/markets/commodities">since mid-July 2024. </a>
This rally comes against a backdrop of intensifying concerns over global supply disruptions and the announcement of a <a href="https://www.benzinga.com/news/global/25/01/43017362/israel-hamas-agree-to-ceasefire-deal-including-hostage-release-biden-confirms">ceasefire in Gaza</a> after a devastating 15-month war.
Crude prices — as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) — haven&#8217;t seen a single-day surge of this magnitude since early October 2024.
<h1 class="wp-block-heading">What's Driving Oil Higher?</h1>
Despite positive geopolitical developments in the Middle East with the ceasefire between Israel and Hamas, traders remain focused on tightening supply fundamentals.
According to Reuters, the ceasefire agreement, brokered by U.S., Egyptian and Qatari diplomats, outlines an Israeli military withdrawal from Gaza and a prisoner exchange.
While this marks a significant step toward de-escalation in the Middle East, oil markets seem more concerned with a series of factors that could constrain global crude flows in the near term.
The Energy Information Administration reported Wednesday a sharper-than-expected decline in U.S. crude inventories for the week ending Jan. 10, further fueling the market&#8217;s bullish sentiment.
Data showed U.S. crude oil inventories fell by 1.961 million barrels last week, exceeding market expectations of a 1.6 million-barrel draw. 
This marked the eighth consecutive weekly decline, pushing U.S. crude commercial stockpiles — excluding the Strategic Petroleum Reserve — to their lowest levels since April 2022.
<h1 class="wp-block-heading">The Impact Of U.S. Sanctions On Russia, Iran</h1>
On Jan. 10, the Biden administration announced sweeping new sanctions targeting Russia. The measures include restrictions on two major Russian producers, Gazprom Neft and Surgutneftegaz, as well as over 160 tankers carrying oil from Russia, Iran, and Venezuela.
The sanctions also complicate ship insurance arrangements, further disrupting logistics for these nations. 
The International Energy Agency, in its latest Oil Market Report released Wednesday, highlighted the potential ramifications of these sanctions, stating:
"Benchmark crude oil prices rallied in early January as U.S. sanctions on Iran and Russia intensified and freezing temperatures swept across large parts of the Northern Hemisphere."
Speculation is mounting that the incoming U.S. administration under President-elect Donald Trump will adopt an even tougher stance on Iran, potentially exacerbating supply constraints. 
"While it is too early to fully quantify the potential impact from these new measures, some operators have reportedly already started to pull back from Iranian and Russian oil," the IEA said.
Freezing temperatures across major oil-consuming regions in the Northern Hemisphere have further tightened energy markets, boosting demand for heating fuels. This seasonal surge in consumption, combined with shrinking inventories and sanctions-related disruptions, leaves the oil market vulnerable to additional supply shocks.
"If decreases in supply from weather impacts, sanctions, or other developments become substantial, oil stocks can quickly be drawn to meet operational requirements in the near term," the IEA stated.
Earlier this week, Goldman Sachs commodity analyst Daan Struyven warned that in a scenario of combined disruptions in Russian and Iranian oil flows, crude prices could rally up <a href="https://www.benzinga.com/markets/25/01/42965857/oil-could-hit-90-goldman-sachs-says-trump-may-not-ease-sanctions-on-russia">to $90 a barrel.</a> 
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43013312/defense-stocks-fall-on-gaza-ceasefire-while-broader-market-rallies-whats-going-on">Defense Stocks Fall On Gaza Ceasefire While Broader Market Rallies: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Specialty ETFs

Commodities

Global

Economics

Oil Prices Break $80, Reach 6-Month Highs Despite Israel-Hamas Ceasefire Deal: Why Is Crude Rallying?

Short-seller Hindenburg Research on Wednesday announced plans to disband the <a href="https://www.benzinga.com/topic/hindenburg-research">New York-based investment firm</a>.
&#8220;The plan has been to wind up after we finished the pipeline of ideas we were working on. And as of the last Ponzi cases we just completed and are sharing with regulators, that day is today,&#8221; Hindenburg founder Nate Anderson said in a blog <a href="https://hindenburgresearch.com/gratitude/">post</a>.
What To Know: Anderson founded Hindenburg Research in 2017. The first half of the letter published on Hindenburg&#8217;s site is a reflection on the success of the company and how it came to be. 
&#8220;Nearly 100 individuals have been charged civilly or criminally by regulators at least in part through our work, including billionaires and oligarchs. We shook some empires that we felt needed shaking,&#8221; Anderson said.
See Also: <a href="https://www.benzinga.com/25/01/43013717/fed-beige-book-flags-moderate-growth-yet-tariffs-immigration-policies-spark-concerns">Fed Beige Book Flags Moderate Growth, Yet Tariffs, Immigration Policies Spark Concerns</a>
About halfway through, Anderson addresses the disbandment, but he said there is no particular reason why. Anderson noted that he felt like he had some things to prove to himself early on, but that he has &#8220;finally found some comfort&#8221; with himself. Anderson also suggested his professional life has taken a toll on his well-being, adding that the &#8220;intensity and focus&#8221; required for the role has come at a cost.
&#8220;Someone once told me that at a certain point a successful career becomes a selfish act,&#8221; he said. 
Anderson said his immediate focus is on finding opportunities for members of the Hindenburg team. Some will be starting their own research firms, while others are seeking different opportunities. 
Anderson also noted he plans to spend the next six months or so working on putting together materials to open-source Hindenburg&#8217;s research model and share how the firm conducted its research so that others may be inspired to do the same.
Hindenburg was the short-selling firm behind some major sell-offs in recent years including <a href="https://www.benzinga.com/short-sellers/23/03/31474945/short-seller-that-sunk-second-richest-man-has-new-target-and-jack-dorsey-is-in-the-crosshairs">Adani Group</a> and Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>). Hindenburg has also targeted big names like Icahn Enterprises L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>), Roblox Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) and most recently, Carvana Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42769626/hindenburg-shorts-carvana-stock-claims-used-car-retailers-turnaround-is-a-mirage">Hindenburg Shorts Carvana Stock, Claims Used Car Retailer&#8217;s Turnaround Is A &#8216;Mirage&#8217;</a></li>
</ul>
Photo: Courtesy of Hindenburg Research.

Short Sellers

Management

CVNA

RBLX

SMCI

Hindenburg Research Is Closing Up Shop: 'We Shook Some Empires That We Felt Needed Shaking'

In a groundbreaking development, Israel and Hamas have reached a ceasefire agreement Wednesday following prolonged conflict in Gaza, reports The Washington Post. The deal, confirmed by U.S. President Joe Biden, aims to halt the hostilities of the past 15 months and facilitate the release of hostages held by Hamas, marking a significant step toward easing tensions in the region.
The agreement requires ratification by a vote of Israel's cabinet. According to Qatar&#8217;s Prime Minister Mohammed bin Abdulrahman Al Thani, implementation of the agreement is set to start Sunday.
<h1 class="wp-block-heading">Key Details of the Ceasefire Agreement</h1>
<ol>
<li>Hostage Release:
<ul>
<li>Hamas has agreed to release hostages, prioritizing women, children and elderly individuals.</li>
<li>The deal includes mechanisms for monitoring and ensuring the safe return of hostages.</li>
</ul>
</li>
<li>Ceasefire Implementation:
<ul>
<li>The agreement entails an immediate cessation of all military operations by both parties.</li>
<li>Israeli forces will initiate a phased withdrawal from Gaza while maintaining a security buffer.</li>
</ul>
</li>
<li>Humanitarian Aid and Reconstruction:
<ul>
<li>Provisions for increased humanitarian assistance to Gaza, including medical supplies, food and essential infrastructure support.</li>
<li>International agencies are expected to oversee aid distribution to ensure it reaches civilians in need.</li>
</ul>
</li>
<li>Prisoner Exchange:
<ul>
<li>In exchange for the release of hostages, Israel will release several Palestinian detainees, with a focus on minors and women.</li>
</ul>
</li>
</ol>
<h1 class="wp-block-heading">International Mediation</h1>
The ceasefire was achieved through intense diplomatic efforts led by Egypt, Qatar and the U.S. Biden played a pivotal role, maintaining direct communication with both Israeli and Palestinian leaders. Steve Witkoff, President-elect Donald Trump's special envoy to the Middle East, also played an instrumental role, said the Washington Post. 
<h1 class="wp-block-heading">Global Reactions</h1>
<ul>
<li>U.S: Biden lauded the agreement as a &#8220;crucial step toward peace&#8221; and pledged continued U.S. support for humanitarian and diplomatic initiatives.</li>
<li>United Nations: Secretary-General António Guterres called the deal a "moment of hope" and urged all parties to abide by its terms.</li>
<li>Public Sentiment: Families of hostages in Israel expressed cautious optimism, while Gaza residents welcomed the cessation of airstrikes and the promise of aid.</li>
</ul>
<h1 class="wp-block-heading">Challenges Ahead</h1>
Despite the breakthrough, challenges remain in implementing and sustaining the agreement. Analysts warn of potential setbacks due to mistrust between the parties and the volatile nature of the region's politics.
The international community has committed to monitoring the situation closely, with hopes that this ceasefire will pave the way for broader negotiations addressing the underlying causes of the conflict.
Photo: Shutterstock

Israel, Hamas Agree To Ceasefire Deal Including Hostage Release, Biden Confirms

The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
&nbsp;Niktimvo is the first and only FDA-approved prescription treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis.

INCY

SNDX

Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February

W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) has outperformed the market over the past 5 years by 14.39% on an annualized basis producing an average annual return of 26.73%. Currently, W.W. Grainger has a market capitalization of $53.38 billion. 
Buying $1000 In GWW: If an investor had bought $1000 of GWW stock 5 years ago, it would be worth $3,269.13 today based on a price of $1093.36 for GWW at the time of writing.
<h3>W.W. Grainger's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736980217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning W.W. Grainger Stock In The Last 5 Years

ImmunityBio responding to requests for information from both Agencies and the potential for approval in European Union and United Kingdom by 2026.
 &nbsp;

IBRX

ImmunityBio Reports Submission Of Applications For ANKTIVA + BCG To EMA And MHRA

ImmunityBio Says Preparing To Submit sBLA In 2025 For Its Treatment Targeting Bacillus Calmette-guérin Unresponsive Non-muscle Invasive Bladder Cancer In The Papillary Indication

The Company intends to announce its preliminary estimated fourth quarter and year-end financial results on an ongoing annual basis due to the predictability of its subscription model and having finalized year-end membership levels.&nbsp;

Life Time Group To Report Preliminary Estimated Q4 Financial Results On January 16

Offerings

Redwood Trust Reports Pricing Of Public Offering Of $90M Of Its 9.125% Senior Notes Due 2030

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 10 years by 13.93% on an annualized basis producing an average annual return of 25.29%. Currently, First Citizens BancShares has a market capitalization of $30.11 billion. 
Buying $1000 In FCNCA: If an investor had bought $1000 of FCNCA stock 10 years ago, it would be worth $9,532.86 today based on a price of $2152.52 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736979313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

Here's How Much $1000 Invested In First Citizens BancShares 10 Years Ago Would Be Worth Today

USAP

Universal Stainless Stockholders Vote At Special Meeting Of Stockholders To Approve Company's Pending Acquisition By Aperam

Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.15 by 8.7 percent. This is a 56.25 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $580.58 million which beat the analyst consensus estimate of $566.59 million by 2.47 percent. This is a 18.81 percent increase over sales of $488.68 million the same period last year.

Earnings

Earnings Beats

Synovus Finl Q4 2024 Adj EPS $1.25 Beats $1.15 Estimate, Sales $580.58M Beat $566.59M Estimate

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price targ...

Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position

H.C. Wainwright says that while Neumora Therapeutics (NMRA)' KOASTAL-1 result "was a surprise and disappointment," the better results for female pa...

H.C. Wainwright still sees opportunity for Neumora despite trial miss

J.P. Morgan analyst Tessa Romero has maintained their neutral stance on NMRA stock, giving a Hold rating yesterday. Tessa Romero has given her Hold...

Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency

Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1/K-1 study data for na...

Neumora shares look oversold after 80% drop, says Mizuho

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), Nater...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely

Trending stocks as Wall Street steps into first days of 2025 with cautiousness

BofA analyst Geoff Meacham lowered the firm's price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares. The ...

Neumora Therapeutics price target lowered to $7 from $22 at BofA

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA – Research Report) and Idexx Lab...

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)

Latest data shows the largest indicative borrow rate increases among liquid option names include: Canoo (GOEV) 135.71% +16.11, AbSci Corp (ABSI) 8....

Largest borrow rate increases among liquid names

AAPL

ABEV

ABSI

AISP

CRNC

GALT

GOEV

IDXX

JAZZ

LCID

LITM

NISTF

NMRA

NPSCY

NTRA

NVDA

PLUG

RGTI

RIVN

SGMT

SMFG

SMFNF

SOFI

SOUN

TSLA

VRAR

Press Releases

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Penny Stocks

Small Cap

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

Comments

Neumora Therapeutics

Noticias

Últimas noticias sobre Neumora Therapeutics (NASDAQ:NMRA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL